ESSA Pharma Inc EPIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
-
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
-
ESSA Pharma to Present at the JonesHealthcare Seaside Summit
Trading Information
- Previous Close Price
- $6.44
- Day Range
- $6.23–6.77
- 52-Week Range
- $2.65–11.67
- Bid/Ask
- $6.29 / $6.84
- Market Cap
- $288.19 Mil
- Volume/Avg
- 1,292 / 55,444
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 50
- Website
- https://www.essapharma.com
Comparables
Valuation
|
Metric
|
EPIX
|
IMU
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.22 | 3.03 | 0.89 |
Price/Sales | — | — | 22.47 |
Price/Cash Flow | — | — | — |
Price/Earnings
EPIX
IMU
NYKD
Financial Strength
|
Metric
|
EPIX
|
IMU
|
NYKD
|
|---|---|---|---|
Quick Ratio | 36.61 | 3.66 | 9.28 |
Current Ratio | 36.95 | 3.86 | 9.28 |
Interest Coverage | −29,635.69 | −321.34 | — |
Quick Ratio
EPIX
IMU
NYKD
Profitability
|
Metric
|
EPIX
|
IMU
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | −15.52% | −67.09% | −17.82% |
Return on Equity (Normalized) | −15.94% | −77.26% | −22.35% |
Return on Invested Capital (Normalized) | −19.88% | −79.58% | −25.52% |
Return on Assets
EPIX
IMU
NYKD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bhhwlmwj | Nzvsx | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dkcplmvws | Shfmbgt | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mymzvghl | Vbddq | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yydryfpl | Pyydr | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Jbdtxqyd | Xvqw | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rxzyfxrp | Pmtzf | $28.1 Bil | |||
| Moderna Inc
MRNA
| Xvsqpfr | Rvtzb | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Grsfdjwxq | Yqk | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mmvhmfv | Fhqkfw | $13.4 Bil | |||
| Incyte Corp
INCY
| Mblgygfkg | Jkwtqn | $12.7 Bil |
United States